Roth Capital Downgrades Cyclacel Pharmaceuticals (CYCC) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Roth Capital downgraded Cyclacel Pharmaceuticals (NASDAQ: CYCC) from Buy to Neutral with a price target of $1.00.
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $0.73 yesterday.
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $0.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades COSCO SHIPPING Holdings Co Ltd (601919:CH) to Sell
- Craig-Hallum Downgrades Alkami Technology Inc (ALKT) to Hold
- JPMorgan Downgrades Jiangxi Copper Co. Ltd. (358:HK) (JIAXF) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
